Epigenetics are thought to play a major role in the carcinogenesis of multiple sporadic colorectal cancers (CRC). Previous studies have suggested concordant DNA hypermethylation between tumor pairs. However, only a few methylation markers have been analyzed. This study was aimed at describing the epigenetic signature of multiple CRC using a genome-scale DNA methylation profiling. We analyzed 12 patients with synchronous CRC and 29 age-, sex-, and tumor location-paired patients with solitary tumors from the EPICOLON II cohort. DNA methylation profiling was performed using the Illumina Infinium HM27 DNA methylation assay. The most significant results were validated by Methylight. Tumors samples were also analyzed for the CpG Island Methylator Phenotype (CIMP); KRAS and BRAF mutations and mismatch repair deficiency status. Functional annotation clustering was performed. We identified 102 CpG sites that showed significant DNA hypermethylation in multiple tumors with respect to the solitary counterparts (difference in β value ≥0.1). Methylight assays validated the results for 4 selected genes (p = 0.0002). Eight out of 12(66.6%) multiple tumors were classified as CIMP-high, as compared to 5 out of 29(17.2%) solitary tumors (p = 0.004). Interestingly, 76 out of the 102 (74.5%) hypermethylated CpG sites found in multiple tumors were also seen in CIMP-high tumors. Functional analysis of hypermethylated genes found in multiple tumors showed enrichment of genes involved in different tumorigenic functions. In conclusion, multiple CRC are associated with a distinct methylation phenotype, with a close association between tumor multiplicity and CIMP-high. Our results may be important to unravel the underlying mechanism of tumor multiplicity.
References
[1]
Chen HS, Sheen-Chen SM (2000) Synchronous and “early” metachronous colorectal adenocarcinoma: analysis of prognosis and current trends. Dis Colon Rectum 43: 1093–1099. doi: 10.1007/bf02236556
[2]
Latournerie M, Jooste V, Cottet V, Lepage C, Faivre J, et al. (2008) Epidemiology and prognosis of synchronous colorectal cancers. Br J Surg 95: 1528–1533. doi: 10.1002/bjs.6382
[3]
Pinol V, Andreu M, Castells A, Paya A, Bessa X, et al. (2004) Synchronous colorectal neoplasms in patients with colorectal cancer: predisposing individual and familial factors. Dis Colon Rectum 47: 1192–1200. doi: 10.1007/s10350-004-0562-7
[4]
Nosho K, Kure S, Irahara N, Shima K, Baba Y, et al. (2009) A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers. Gastroenterology 137: 1609–1620 e1601–1603. doi: 10.1053/j.gastro.2009.08.002
[5]
Ogino S, Brahmandam M, Kawasaki T, Kirkner GJ, Loda M, et al. (2006) Epigenetic profiling of synchronous colorectal neoplasias by quantitative DNA methylation analysis. Mod Pathol 19: 1083–1090. doi: 10.1038/modpathol.3800618
[6]
Shen L, Kondo Y, Rosner GL, Xiao L, Hernandez NS, et al. (2005) MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 97: 1330–1338. doi: 10.1093/jnci/dji275
[7]
Young J, Jass JR (2006) The case for a genetic predisposition to serrated neoplasia in the colorectum: hypothesis and review of the literature. Cancer Epidemiol Biomarkers Prev 15: 1778–1784. doi: 10.1158/1055-9965.epi-06-0164
[8]
Dykes SL, Qui H, Rothenberger DA, Garcia-Aguilar J (2003) Evidence of a preferred molecular pathway in patients with synchronous colorectal cancer. Cancer 98: 48–54. doi: 10.1002/cncr.11445
[9]
Lawes DA, Pearson T, Sengupta S, Boulos PB (2005) The role of MLH1, MSH2 and MSH6 in the development of multiple colorectal cancers. Br J Cancer 93: 472–477.
[10]
Pedroni M, Tamassia MG, Percesepe A, Roncucci L, Benatti P, et al. (1999) Microsatellite instability in multiple colorectal tumors. Int J Cancer 81: 1–5. doi: 10.1002/(sici)1097-0215(19990331)81:1<1::aid-ijc1>3.0.co;2-k
[11]
Balaguer F, Castellvi-Bel S, Castells A, Andreu M, Munoz J, et al. (2007) Identification of MYH mutation carriers in colorectal cancer: a multicenter, case-control, population-based study. Clin Gastroenterol Hepatol 5: 379–387. doi: 10.1016/j.cgh.2006.12.025
[12]
Lynch HT, de la Chapelle A (2003) Hereditary colorectal cancer. N Engl J Med 348: 919–932. doi: 10.1056/nejmra012242
[13]
Chan AO, Issa JP, Morris JS, Hamilton SR, Rashid A (2002) Concordant CpG island methylation in hyperplastic polyposis. Am J Pathol 160: 529–536. doi: 10.1016/s0002-9440(10)64872-9
[14]
Kamiyama H, Suzuki K, Maeda T, Koizumi K, Miyaki Y, et al. (2012) DNA demethylation in normal colon tissue predicts predisposition to multiple cancers. Oncogene 31: 5029–5037. doi: 10.1038/onc.2011.652
[15]
Minoo P, Baker K, Goswami R, Chong G, Foulkes WD, et al. (2006) Extensive DNA methylation in normal colorectal mucosa in hyperplastic polyposis. Gut 55: 1467–1474. doi: 10.1136/gut.2005.082859
[16]
Giovannucci E, Ogino S (2005) DNA methylation, field effects, and colorectal cancer. J Natl Cancer Inst 97: 1317–1319. doi: 10.1093/jnci/dji305
[17]
Gonzalo V, Lozano JJ, Munoz J, Balaguer F, Pellise M, et al. (2010) Aberrant gene promoter methylation associated with sporadic multiple colorectal cancer. PLoS One 5: e8777. doi: 10.1371/journal.pone.0008777
[18]
Konishi K, Shen L, Jelinek J, Watanabe Y, Ahmed S, et al. (2009) Concordant DNA methylation in synchronous colorectal carcinomas. Cancer Prev Res (Phila) 2: 814–822. doi: 10.1158/1940-6207.capr-09-0054
[19]
Gonzalo V, Castellvi-Bel S, Balaguer F, Pellise M, Ocana T, et al. (2008) [Epigenetics of cancer]. Gastroenterol Hepatol 31: 37–45. doi: 10.1157/13114573
[20]
Bardhan K, Liu K (2013) Epigenetics and colorectal cancer pathogenesis. Cancers (Basel) 5: 676–713. doi: 10.3390/cancers5020676
[21]
Colussi D, Brandi G, Bazzoli F, Ricciardiello L (2013) Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci 14: 16365–16385. doi: 10.3390/ijms140816365
[22]
Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, et al. (2003) Induction of tumors in mice by genomic hypomethylation. Science 300: 489–492. doi: 10.1126/science.1083558
[23]
Holm TM, Jackson-Grusby L, Brambrink T, Yamada Y, Rideout WM 3rd, et al. (2005) Global loss of imprinting leads to widespread tumorigenesis in adult mice. Cancer Cell 8: 275–285. doi: 10.1016/j.ccr.2005.09.007
[24]
Abuli A, Bessa X, Gonzalez JR, Ruiz-Ponte C, Caceres A, et al. (2010) Susceptibility genetic variants associated with colorectal cancer risk correlate with cancer phenotype. Gastroenterology 139: 788–796, 796 e781–786. doi: 10.1053/j.gastro.2010.05.072
[25]
Bibikova M, Le J, Barnes B, Saedinia-Melnyk S, Zhou L, et al. (2009) Genome-wide DNA methylation profiling using Infinium(R) assay. Epigenomics 1: 177–200. doi: 10.2217/epi.09.14
Hinoue T, Weisenberger DJ, Lange CP, Shen H, Byun HM, et al. (2012) Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res 22: 271–282. doi: 10.1101/gr.117523.110
[28]
Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, et al. (2000) MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 28: E32. doi: 10.1093/nar/28.8.e32
[29]
Perez-Carbonell L, Ruiz-Ponte C, Guarinos C, Alenda C, Paya A, et al. (2012) Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer. Gut 61: 865–872. doi: 10.1136/gutjnl-2011-300041
[30]
Goel A, Xicola RM, Nguyen TP, Doyle BJ, Sohn VR, et al. (2010) Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. Gastroenterology 138: 1854–1862. doi: 10.1053/j.gastro.2010.01.035
[31]
Giraldez MD, Balaguer F, Bujanda L, Cuatrecasas M, Munoz J, et al. (2010) MSH6 and MUTYH deficiency is a frequent event in early-onset colorectal cancer. Clin Cancer Res 16: 5402–5413. doi: 10.1158/1078-0432.ccr-10-1491
[32]
Jiao X, Sherman BT, Huang da W, Stephens R, Baseler MW, et al. (2012) DAVID-WS: a stateful web service to facilitate gene/protein list analysis. Bioinformatics 28: 1805–1806. doi: 10.1093/bioinformatics/bts251
[33]
Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, et al. (2006) CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38: 787–793. doi: 10.1038/ng1834
[34]
Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, et al. (2012) Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 61: 847–854. doi: 10.1136/gutjnl-2011-300865
[35]
Zauber P, Huang J, Sabbath-Solitare M, Marotta S (2013) Similarities of molecular genetic changes in synchronous and metachronous colorectal cancers are limited and related to the cancers' proximities to each other. J Mol Diagn 15: 652–660. doi: 10.1016/j.jmoldx.2013.03.009
[36]
Ferracin M, Gafa R, Miotto E, Veronese A, Pultrone C, et al. (2008) The methylator phenotype in microsatellite stable colorectal cancers is characterized by a distinct gene expression profile. J Pathol 214: 594–602. doi: 10.1002/path.2318
[37]
Mullany SA, Moslemi-Kebria M, Rattan R, Khurana A, Clayton A, et al. (2011) Expression and functional significance of HtrA1 loss in endometrial cancer. Clin Cancer Res 17: 427–436. doi: 10.1158/1078-0432.ccr-09-3069
[38]
Catalano V, Mellone P, d'Avino A, Shridhar V, Staccioli MP, et al. (2011) HtrA1, a potential predictor of response to cisplatin-based combination chemotherapy in gastric cancer. Histopathology 58: 669–678. doi: 10.1111/j.1365-2559.2011.03818.x
[39]
Lorenzi T, Lorenzi M, Altobelli E, Marzioni D, Mensa E, et al. (2013) HtrA1 in human urothelial bladder cancer: A secreted protein and a potential novel biomarker. Int J Cancer doi: 10.1002/ijc.28280
[40]
Zuo X, Peng Z, Wu Y, Moussalli MJ, Yang XL, et al. (2012) Effects of gut-targeted 15-LOX-1 transgene expression on colonic tumorigenesis in mice. J Natl Cancer Inst 104: 709–716. doi: 10.1093/jnci/djs187
[41]
Joensuu EI, Abdel-Rahman WM, Ollikainen M, Ruosaari S, Knuutila S, et al. (2008) Epigenetic signatures of familial cancer are characteristic of tumor type and family category. Cancer Res 68: 4597–4605. doi: 10.1158/0008-5472.can-07-6645
[42]
Kim YH, Petko Z, Dzieciatkowski S, Lin L, Ghiassi M, et al. (2006) CpG island methylation of genes accumulates during the adenoma progression step of the multistep pathogenesis of colorectal cancer. Genes Chromosomes Cancer 45: 781–789. doi: 10.1002/gcc.20341
